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Abstract
We performed a genome-wide association (GWA) study in 434 sporadic Creutzfeldt-Jakob
disease (sCJD) patients and 1939 controls from the United Kingdom, Germany and The
Netherlands. The findings were replicated in an independent sample of 1109 sCJD and
2264 controls provided by a multinational consortium. From the initial GWA analysis we se-
lected 23 SNPs for further genotyping in 1109 sCJD cases from seven different countries.
Five SNPs were significantly associated with sCJD after correction for multiple testing.
Subsequently these five SNPs were genotyped in 2264 controls. The pooled analysis, in-
cluding 1543 sCJD cases and 4203 controls, yielded two genome wide significant results:
rs6107516 (p-value=7.62x10-9) a variant tagging the prion protein gene (PRNP); and
rs6951643 (p-value=1.66x10-8) tagging the Glutamate Receptor Metabotropic 8 gene
(GRM8). Next we analysed the data stratifying by country of origin combining samples from
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the pooled analysis with genotypes from the 1000 Genomes Project and imputed genotypes
from the Rotterdam Study (Total n=12967). The meta-analysis of the results showed that
rs6107516 (p-value=3.00x10-8) and rs6951643 (p-value=3.91x10-5) remained as the two
most significantly associated SNPs. Rs6951643 is located in an intronic region ofGRM8,
a gene that was additionally tagged by a cluster of 12 SNPs within our top100 ranked re-
sults. GRM8 encodes for mGluR8, a protein which belongs to the metabotropic glutamate
receptor family, recently shown to be involved in the transduction of cellular signals trig-
gered by the prion protein. Pathway enrichment analyses performed with both Ingenuity
Pathway Analysis and ALIGATOR postulates glutamate receptor signalling as one of the
main pathways associated with sCJD. In summary, we have detected GRM8 as a novel,
non-PRNP, genome-wide significant marker associated with heightened disease risk, pro-
viding additional evidence supporting a role of glutamate receptors in sCJD pathogenesis.
Introduction
Sporadic Creutzfeldt-Jakob disease (sCJD), although rare, with a yearly incidence of one to two
cases per million, is the most common form of human prion disease. This group of disorders is
characterized by spongiform changes in the brain, as well as accumulation of misfolded, often
protease-resistant, conformers (PrPSc) of the normal prion protein (PrPC). The PrPC gene
(PRNP) plays a central role in prion disease susceptibility. Expression of PrPC is indispensable
for disease transmission [1] and the polymorphism coding for methionine (M) or valine (V) at
codon 129 (PRNPM129V) has been linked to disease risk [2]. Homozygosity at PRNPM129V
has been consistently associated to sCJD, being one of the strongest common genetic risk fac-
tors reported for neurodegenerative diseases. The remarkable disease-determining effect of this
PRNP polymorphism is observed in variant CJD, a subtype acquired from dietary exposure to
bovine spongiform encephalopathy [3], where all definite and probable clinical cases studied to
date have been PRNP129MM [4].
Similar to other diseases, several genetic association studies with candidate genes have been
performed on sCJD susceptibility [5]. Only one previous genome wide association study
(GWAS) of sCJD risk has been published to date, showing that the PRNP locus was strongly as-
sociated with disease risk, specifically with rs1799990 (PRNPM129V) [6].
To further scrutinize genomic variations related to sCJD risk we have performed a three-
stage GWAS encompassing a total of 1,543 sCJD cases and 4,203 controls, as well as a meta-
analysis encompassing data from the 1000 Genomes Project and imputations from the Rotter-
dam Study.
Results
Demographic and clinical features of the sCJD case populations are shown in S1 Table. The
Q-Q plots for autosomal and X chromosome SNPs are given in S1 Fig; during discovery (stage
one) the genomic inflation factor λ was 1.053 for autosomal and 1.057 for X chromosome
SNPs.
S2 Table shows the top 100 SNPs associated with sCJD at discovery stage, sorted by allelic
differences p-value. A total of 23 SNPs were taken forward to replication. In stage two, we suc-
cessfully genotyped 22 of the 23 SNPs with the Sequenom iPLEx GOLD platform in an indepen-
dent population of 1,109 samples of sCJD. Table 1 shows that five SNPs remained significant
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Table 1. SNPs genotyped in stage two.
Stage one: Discovery Stage two: Replication in
independent sCJD Cases
SNP CJD risk allele in
Discovery
population
GENE tagged Controls Frequencies
of sCJD risk allele
(n = 1939)
Cases Frequencies
of sCJD risk allele
(n = 434)
P1df* Cases Frequencies of
sCJD risk allele
(n = 1109)
P-value**
rs10061929 A FLJ43080 0.159 0.224 4.58E-
05
0.200 5.89E-05
rs10915708 T NA 0.140 0.207 1.35E-
06
0.158 0.0626
rs11075924 C NA 0.498 0.565 5.52E-
05
0.500 0.8808
rs11245373 T NA 0.037 0.069 2.48E-
05
0.049 0.0238
rs12102156 T NA 0.863 0.912 2.00E-
05
0.849 0.1457
rs12188818 C NA 0.796 0.859 6.44E-
05
0.809 0.2544
rs12419710 A NA 0.210 0.279 2.52E-
05
0.219 0.3746
rs17060736 G NA 0.112 0.160 7.13E-
05
0.121 0.3134
rs17115017 A GRIA1 0.050 0.082 2.23E-
04
0.072 5.00E-04
rs17833759 C GRIN2B 0.085 0.140 7.74E-
07
0.095 0.1955
rs196940 C ERN1 0.758 0.818 6.19E-
05
0.758 0.9631
rs2240344 G NA 0.432 0.600 4.47E-
19
0.443 0.4194
rs2627829 A INPP4B 0.939 0.970 1.83E-
04
0.931 0.2188
rs392184 T MACROD2 0.052 0.096 2.00E-
06
0.07 0.003
rs565559 T NA 0.553 0.618 2.02E-
04
0.579 0.057
rs6027482 C LOC100131710 0.187 0.247 6.69E-
05
0.181 0.5476
rs6107516 C PRNP 0.752 0.827 6.92E-
06
0.804 3.27E-06
rs6463269 G NA 0.084 0.134 3.53E-
06
GENOTYPE FAILED -
rs6496239 T NA 0.805 0.862 4.96E-
05
0.821 0.1195
rs6820644 T NA 0.357 0.433 3.40E-
06
0.647 0.7566
rs6951643 A GRM8 0.507 0.592 8.09E-
06
0.573 6.79E-07
rs9521699 A COL4A2 0.137 0.194 3.84E-
05
0.173 2.00E-04
(Continued)
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after Bonferroni correction. In stage three we genotyped those five SNPs in a population of
2,264 independent controls with Sequenom iPLEx GOLD. S2 Fig depicts neatly separated geno-
type clusters of the five SNPs studied in stage three. Only two SNPs were successfully replicated
at stage three and reached genome wide significant p-values after meta-analysis of discovery
and replication results: rs6107516 (p-value = 7.62x10-9) tagging PRNP and in linkage disequilib-
rium (LD) with PRNPM129V (rs1799990), and rs6951643 (p-value = 1.66x10-8) an intronic
SNP withinGRM8 (Glutamate Receptor Metabotropic 8) in chromosome 7. Table 2 shows dif-
ferences in allelic frequencies in the discovery, replication and pooled population sets including
1,543 sCJD cases and 4,203 controls. The A allele of rs6951643 was associated with a 1.27 fold
increased risk of sCJD (95%CI = 1.17–1.38), and this effect was consistently observed across all
tested populations (Table 3).
Rs6107516 (p-value = 3.00x10-8) and rs6951643 (p-value = 3.91x10-5) remained as the two
most statistically significant associations in a meta-analysis of the discovery data adjusted for
PCAs and analysis of replication samples stratified by country. This meta-analysis included
discovery and replication samples plus data from the 1000 Genomes Project and imputed geno-
types from the Rotterdam Study (Total n = 12967), (Table 4). Within the top 100 SNPs, there
Table 1. (Continued)
Stage one: Discovery Stage two: Replication in
independent sCJD Cases
SNP CJD risk allele in
Discovery
population
GENE tagged Controls Frequencies
of sCJD risk allele
(n = 1939)
Cases Frequencies
of sCJD risk allele
(n = 434)
P1df* Cases Frequencies of
sCJD risk allele
(n = 1109)
P-value**
rs9830696 T NA 0.120 0.173 1.02E-
05
0.104 0.0711
sCJD: Sporadic Creutzfeldt-Jakob Disease
In bold SNPs signiﬁcant after Bonferroni correction (Replication P-value <0.0023)
* P-value for allellic diferences adjusted by Country of origin by PCA
**Chi Squared p-value from comparison between Allele frequencies of independent sCJD cases and stage one controls
NA: SNP in intergenic region.
doi:10.1371/journal.pone.0123654.t001
Table 2. SNPs studied in stage three.
Discovery Population Replication Population Pooled Samples
ID CJD risk
allele in
Discovery
population
GENE
tagged
Case, Control
Frequencies of
CJD risk allele
(n = 434,
n = 1939)
P-value P-value* OR
(95%CI)
Case, Control
Frequencies of
CJD risk allele
(n = 1109,
n = 2264)
P-value OR
(95%CI)
Case.Control
Frequencies of
CJD risk allele
(n = 1543,
n = 4203)
P-value OR
(95%CI)
rs10061929 A FLJ43080 0.224, 0.159 4.30E-
06
4.58E-05 1.53
(1.27–1.83)
0.200, 0.196 0.6882 1.03
(0.90–1.17)
0.207, 0.179 0.0007 1.20
(1.08–1.33)
rs17115017 A GRIA1 0.082, 0.050 3.00E-
04
2.23E-04 1.69
(1.27–2.24)
0.072, 0.077 0.4434 1.08
(0.89–1.31)
0.075, 0.065 0.0597 1.17
(0.99–1.37)
rs6107516 C PRNP 0.827, 0.752 2.07E-
06
6.92E-06 1.58
(1.31–1.91)
0.804, 0.766 5.00E-
04
1.25
(1.10–1.42)
0.811, 0.759 7.62E-
09
1.35
(1.22–1.50)
rs6951643 A GRM8 0.592, 0.507 6.73E-
06
8.09E-06 1.41
(1.21–1.64)
0.573, 0.529 7.00E-
04
1.19
(1.08–1.32)
0.578, 0.519 1.66E-
08
1.27
(1.17–1.38)
rs9521699 A COL4A2 0.194, 0.137 2.41E-
05
3.84E-05 1.51
(1.25–1.83)
0.173, 0.173 0.9723 1.00
(0.88–1.15)
0.179, 0.157 0.0045 1.17
(1.05–1.31)
* Adjusted by Country of origin by PCA.
doi:10.1371/journal.pone.0123654.t002
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were 12 tagging GRM8 (S2 Table). Pathway analysis using IPA showed that glutamate
receptor signalling was the most over-represented canonical pathway within our top results
(p-value = 8.01x10-5) (Fig 1). Analysis with ALIGATOR software showed (S3 Table) that the
GO category glutamate receptor activity was the 4th most represented amongst our top results.
Three genes from the GO category "glutamate receptor pathway" (S2 Table) were within our
top 100 SNPs (GRM8, GRIN2B and GRIA1). Fine mapping in search for functional variants
linked to rs6951643 was attempted sequencing the 11 exons of GRM8 gene and the corre-
sponding intronic flanking regions in 96 sCJD patients. We found 8 intronic SNPs
(rs73231278, rs62468898, rs1008274, rs111546739, rs17685327, rs6951643, rs2074012,
rs35648111) and one exonic non-coding SNP (rs34182595). Functional prediction analysis of
these genetic variants by FuncPred or RESCUE-ESE showed no indication of regulatory impli-
cations. In the Gtex eQTL database we found no eQTL associated to any of the GRM8 SNPs.
There is no co-expression of GRM8 and PRNP in blood eQTLs in Genenetwork. However,
based on PITA prediction we found that rs34182595, which is an insertion/deletion SNP in
Table 3. - rs6951643 pooled genotypes by country.
Population GG n (%) AG n (%) AA n (%) A allele n (%) G allele n (%)
CONTOLS
UK 364 (24.6) 741 (50.0) 377 (25.4) 1495 (50.4) 1469 (49.6)
NL 118 (22.4) 265 (50.3) 144 (27.3) 553 (52.5) 501 (47.5)
Spain 488 (22.3) 1097 (50.0) 608 (27.7) 2313 (52.7) 2073 (47.3)
CASES
UK 28 (10.5) 155 (58.3) 83 (31.2) 321 (60.3) 211 (39.7)
NL 23 (18.1) 62 (48.8) 42 (33.1) 146 (57.5) 108 (42.5)
Germany 66 (16.7) 217 (54.8) 113 (28.5) 443 (55.9) 349 (44.1)
Italy 43 (15.0) 140 (48.8) 104 (36.2) 348 (60.6) 226 (39.4)
Australia 10 (20.8) 26 (54.2) 12 (25.0) 50 (52.1) 46 (47.9)
France 23 (15.3) 77 (51.3) 50 (33.3) 177 (59.0) 123 (41.0)
Spain 35 (17.2) 110 (54.2) 58 (28.6) 226 (55.7) 180 (44.3)
Austria 11 (20.0) 27 (49.1) 17 (30.9) 61 (55.5) 49 (44.5)
ALL CONTOLS 970 (23.1) 2103 (50.0) 1129 (26.9) 4361 (51.9) 4043 (48.1)
ALL CASES 239 (15.6) 814 (53.1) 479 (31.3) 1772 (57.8) 1292 (42.2)
HapMap Frequencies (CEU) 27 (23.9) 59 (52.2) 27 (23.9) 113 (0.50) 113 (0.50)
doi:10.1371/journal.pone.0123654.t003
Table 4. Meta-analysis by country of origin.
MarkerName Effect estimates of discovery
analysis corrected for
population substructure by PCA
Meta-analysis of effect estimates of replication
analysis stratiﬁed by country of origin
Meta-analysis of discovery and
replication
β SE P-value β SE P-value β Direction* β SE P-value
rs6107516 0.4243 0.0944 6.92E-06 0.2327 0.0637 0.000262 ₊₊₊₊₊ 0.2927 0.0528 3.00E-08
rs17115017 -0.5363 0.1453 0.000223 -0.1420 0.1061 0.181 ₋₋₋₊₊ -0.2792 0.0857 0.001123
rs9521699 -0.4087 0.0993 3.84E-05 -0.0233 0.0723 0.7468 ₊₋₊₋₋ -0.157 0.0585 0.007242
rs6951643 -0.3472 0.0778 8.09E-06 -0.1033 0.0545 0.05821 ₋₊₊₊₊ -0.1837 0.0447 3.91E-05
rs10061929 -0.3737 0.0917 4.58E-05 -0.0289 0.0701 0.6801 ₋₋₋₊₊ -0.1562 0.0557 0.005048
* Concordance between discovery population βs and each of the ﬁve replication populations; PCA, Principal Component Analysis; SE, standard Error.
doi:10.1371/journal.pone.0123654.t004
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exon 11 in partial LD with rs6951643 (D' = 0.41; r2 = 0.16), is located in a target site for micro-
RNAs (miR-103 and miR-107), a finding that has been previously reported [7].
We then performed an immunohistochemical study in brain samples from 48 sCJD pa-
tients. Immunoreactivity for mGluR8 was observed in neurons and microglial cells (both in the
white and grey matter) While in neurons we did not observe obvious differences we found a
trend towards higher combined score of mGluR8 immunoreactivity in microglia related to the
A allele at rs6951643 (Fig 2); however, these differences were not statistically significant (ordi-
nal regression A-carriers versus A-non-carriers adjusting by c129 and levels of microglia in
temporal cortex; p-value = 0.093). S3 Fig shows semi-quantitative assessments of mGluR8
expression in microglia (0 to 3) in the temporal region across the three rs6951643 genotypes.
We found no association between rs6951643 genotypes and patient’s age of disease onset or
disease duration.
Discussion
In this study we report a non-PRNP genetic risk variant for sCJD, GRM8. Moreover, building
on findings from previous studies [8], pathway analyses yielded glutamate receptor signalling
as one of the main pathways linked to sCJD pathogenesis.
A previous GWAS of prion diseases employed 1,259 sCJD samples, in addition to other dis-
ease subtypes and 6,015 shared controls [6]. In the sCJD sub-group and in a meta-analysis in-
cluding all prion cases only variants in PRNP were found to be significantly associated with
disease risk. Several SNPs outside PRNP were identified, but in contrast to our multi-national
disease cohort the association with sCJD was not homogeneous across the different geographi-
cal groups. Our main novel finding (rs6951643) was not statistically significant in that analysis.
One possible explanation for this discrepancy is the fact that both studies have limited power
to detect small effects due to the overall restricted case numbers included for study and there-
fore a SNP with a relatively modest OR of 1.27 might not be detected by all analyses. The expe-
rience and insights drawn from GWAS performed in more prevalent disorders, such as
Alzheimer’s disease, shows that increasing sample size and performing meta-analysis might be
essential in order to discover and confirm, relatively small-effect genetic risk factors. However,
it is worth re-iterating that in our study, the association with rs6951643 was consistent across
Fig 1. Canonical pathway analysis performed by IPA software including those genes tagged by SNPs with p-value <0.001 in our GWAs analysis.
The horizontal axis represents the pathways identified. The ratio (vertical axis, right) is calculated by the numbers of genes in a given pathway that meet
cutoff criteria, divided by total numbers of genes that make up that pathway. The orange line stands for the threshold above which there are statistically
significantly (by default P<0.05). The vertical axis (left) shows the −log of the p-value calculated based on Fisher’s exact test.
doi:10.1371/journal.pone.0123654.g001
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the geographically diverse sCJD population tested, showing an over-representation of the A al-
lele in cases, and across the different genotyping methods used.
A limitation of our primary analysis was the fact that we were not able to adjust by country
of origin at the replication stage. In order to overcome this caveat we performed a meta-
analysis including control data from the 1000 Genomes Project and imputed data from the Rot-
terdam Study. In the meta-analysis of the stratified analysis by country of origin the association
of both SNPs became less significant suggesting that some signal might be caused by popula-
tion stratification. Despite the fact that both variants were nominally significant in the meta-
analysis of the replication data, the PRNP variant was the only genome wide significantly asso-
ciated to sCJD in the pooled meta-analysis. However, this meta-analysis is not perfect either, as
ideally the cases and controls should originate from the same population and in our analysis
we attempted to match on country of origin (see S4 Table) and this approach is statistically less
powerful because of the uneven distribution of cases and controls, as might reflect the fact that
the PRNP SNP p-value is also less significant in the meta-analysis than in the primary analysis.
Still we acknowledge that the results are a call for caution and the association between GRM8
genetic variants and sCJD should be confirmed in larger analysis with extensive control for
population stratification.
Fig 2. Representative photomicrographs of a sCJD case with AA (a, c) and a sCJD case with GG (b, d) rs6951643 genotype showing differences in
mGluR8 immunostaining of microglial cells in the temporal cortex (a, b) and temporal white matter (c, d). Bar represents 50 μm for all images.
doi:10.1371/journal.pone.0123654.g002
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GRM8 encodes for mGluR8, a protein that belongs to the metabotropic glutamate receptor
family, a family that has recently been linked to the transduction of physiological and cytotoxic
signals mediated by PrPC. MGluR1 and mGluR5 have been shown to interact with PrPC, with
such associations appearing important for promoting neurite outgrowth [9, 10]. Additionally,
a recent study demonstrated that mGluR5 coupled with PrPC mediated the cellular toxicity of
soluble β-amyloid oligomers [10]. Further, in the APPswe/PS1dE9 Alzheimer’s disease mouse
model, altered PrPC processing and a selective increase in cortical mGluR1 expression has been
reported. The authors hypothesized that complex processing of PrPC in connection with
mGluR1 over-expression is triggered by β-amyloid peptides [11]. In the setting of accumula-
tion of PrPSc, our immunohistochemical assessment of a limited sample of sCJD patients
found that carriers of the risk allele at rs6951643 tended to have higher mGluR8 expression in
microglial cells compared to non-carriers. Although our functional prediction analysis for
rs6951643 was uninformative, it is of interest that a nearby variant in partial LD (rs34182595)
is located in a micro-RNA target site and could influence gene expression.
In conclusion, our study has detected a GRM8 genetic variant as a suggestive marker for
sCJD risk mapping outside the PRNP region. Our findings provide evidence supporting a role
for glutamate receptor signalling pathways in sCJD susceptibility. The involvement of gluta-
mate receptor pathway in sCJD should be addressed in future studies in order to provide new
insights in its pathogenesis. Our results underscore the importance of increasing sample sizes
in future studies in order to augment the likelihood of detecting additional non-PRNP genetic
risk factors for sCJD.
Methods
Ethics statement
The present study was conducted according to the revised Declaration of Helsinki and Good
Clinical Practice guidelines. A signed informed consent to participate in genetic research was
obtained from all participants or patients’ relatives. The study was approved by Comité de
Ética de la Investigación y de Bienestar Animal (CEIyBA), National Health Institute Carlos III
and Comité de Ética de Ensayos clínicos de Galicia and Comite de Ética de la Fundación Pú-
blica Gallega de Medicina Genómica (Servicio Gallego de Salud, SERGAS) (Spain); the Lothian
Health Board, Lothian Research Ethics Committee (reference MCO/103/90) (UK); the Ethik-
Kommission der Universitätsmedizin Göttingen (No. 9/6/0) (Germany); the Ethic Committee
of the Istituto Superiore di Sanità (CE-ISS 09/266) (Italy); the Medical Ethics Committee of
The Erasmus MC and the review board of The Netherlands Ministry of Health Welfare and
Sports (The Netherlands); the Ethics Committee of the Medical University of Vienna (396/
2011) (Austria); the Human Research Ethics Committee, based at The University of Melbourne
(941450) (Australia).
Populations and study design
All patients were ascertained by National CJD Surveillance Centers. Only definite or probable
sCJD cases, according to accepted classification criteria, were included [12]. Table 5 summa-
rizes the study design and populations included after quality control. All cases and controls
were of Caucasian origin. Legal representatives gave written informed consent, and all samples
were taken in accordance with the Helsinki declaration.
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Genotyping and quality control
At the discovery stage (stage one) patient’s samples were characterized using the Affymetrix
500k array at the USC node of the Spanish National Genotyping Center. Out of the initially
available 554 sCJD samples there was not enough DNA in 61 (36 samples from the UK and 25
from Germany), leaving 493 for genotyping. Genotypes were called first by the Dynamic
Model (DM) and those samples with an overall call rate>93% were subsequently called by a
Bayesian Robust linear model with Mahalanobis distance (BRLMM). Samples with BRLMM
call rates<95% and with call and discrimination rates of the Modified Partitioning Around
Medoids algorithm (MDR-MCR)>10% were excluded (31 patient samples out of 493 did not
reach these thresholds, leaving in total 462 available for the analysis). Genotype and quality
control of the WTCCC controls have been described elsewhere [13]. The other set of controls
(Rotterdam Study) were genotyped at the Genetic Laboratory, Department of Internal Medi-
cine at Erasmus Medical Center (Rotterdam) also using the Afymmetrix 500K array following
same protocols as those used for cases. After quality control, 28 patients and 25 controls were
excluded resulting in a final discovery population of 434 sCJD patients and 1,939 controls. Rep-
lication was attempted in independent sCJD patients (n = 1,201) (stage two) and control series
Table 5. Study Design and populations tested.
STAGES POPULATION EFFECTIVELY ASSESSED*
sCJD CASES (N) CONTROLS (N)
Stage 1: Discovery Germany (113)
Genotyping method: Affymetrix 500k array UK (269) UK WTCCC controls (1482)
Number of SNPs effectively assessed 279389 Netherlands (52) Netherlands-RS controls (457)
Number of SNPs selected for replication: 23 TOTAL sCJD (434) TOTAL controls (1939)
Stage 2: Replication in independent sCJD Cases Germany (284)
Genotyping method: Sequenom iPLEX GOLD Netherlands (76)
Number of SNPs effectively assessed: 22 Italy (292)
Number of SNPs replicated: 5 Australia (48)
France (150)
Spain (203)
Austria (56)
TOTAL sCJD (1109)
Stage 3: Replication in independent Controls Spain-USC (2193)
Genotyping method: Sequenom iPLEX GOLD Netherlands-RS (71)
Number of SNPs effectively assessed: 5 TOTAL controls (2264)
Number of SNPs replicated: 2
TOTAL controls (4203)
POOLED ANALYSIS TOTAL sCJD (1543)
Netherlands-RS (6192)
British in England and Scotland-10KG (137)
Controls added in analysis stratiﬁed by country Toscani in Italy-10KG (385)
Iberian populations in Spain-10KG (217)
Utah residents with Northern and Western European ancestry-10KG (290)
TOTAL sCJD (1543) TOTAL controls (11424)
*Number of samples effectively genotyped that passed quality control
sCJD, sporadic Creutzfeldt-Jakob disease; WTCCC, Welcome Trust Case Control Consortium; RS, Rotterdam Study; USC, University of Santiago de
Compostela; 10KG, 1000 Genome Project.
doi:10.1371/journal.pone.0123654.t005
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(n = 2,264) (stage three) with the Sequenom iPLEx GOLD platform. SNPs for replication were
selected as follows: after excluding outliers, we chose the 10 SNPs with lowest p-values (when a
cluster of SNPs was in LD tagging the same gene we selected only the one with lowest p-value)
and the remainder from the top 100 when a) they were in linkage disequilibrium with other
top 100 SNPs or b) agreed in direction with the previous sCJD GWAS [6], or c) were connected
to pathways of interest based on our previous study [14] (phosphatidylinositol) or based on the
pathway analyses performed with the current data (glutamate receptors).
Statistical analysis of genetic data
The statistical analyses were conducted using GenABEL [15]. For the individual SNP analysis,
we excluded those SNPs: 1) with call rates<98% within either group (n = 219,182); 2) with
minor allele frequency<0.01 (n = 1); 3) with controls not in Hardy-Weinberg equilibrium
(False Discovery Rate for unacceptably high individual heterozygosity<1%) (n = 1,300). The
quality control further included a check of the sex chromosomes against the reported sex and
unexpected sample duplicates (Identity by State, IBS>95%). All quality control was performed
with the ‘check.marker’ function of GenABEL. After quality control, 279,389 out of 499,872
SNPs were included in the analyses. In the discovery analyses (stage one), we conducted a one
degree of freedom additive score test between cases and controls coding the presence of the
minor genotype 0 for non-carriers, 1 for heterozygous and 2 for homozygous carriers. We con-
trolled subpopulation structure using principal components analysis (PCA). In brief, we select-
ed a random set of 10,000 SNPs and calculated a genomic kinship matrix using pair wise
identity by state statistic (function 'ibs'). We then performed PCA analysis (function
'cmdscale'), and adjusted our analysis by the three main IBS matrix principal components
(function 'mlreg'). We calculated the genomic inflation factor lambda (λ) for both autosomal
and X chromosome SNPs. In the replication phase (stages two and three), we compared allele
frequencies in cases and controls by a Chi-squared test implemented in Haploview [16]. We
used a Bonferroni correction to adjust for multiple testing, setting the threshold for significance
to a p-value of 0.0023 (0.05/22 SNPs successfully genotyped). We combined the gene discovery
and replication series of patients for all validated SNPs and used as the criterion for genome
wide significance a p-value of 5x10-8. We attempted to adjust for country of origin after stage
three. We analysed the data from stage two and three with genotypes of the 1000 Genomes Proj-
ect [17] and imputed genotypes from the Rotterdam Study [18]. We extracted the SNPs from
the 1000 Genomes reference set excluding the children and other family members (Version:
phase I v3). Additionally we imputed the same SNPs from the Rotterdam Study (imputations
of the same phase I v3of the 1000 Genomes). Imputed genotypes had a very high quality score
(R2> = 0.99). Next we paired our cases and controls by country of origin (S4 Table) and calcu-
lated effect estimates of the SNPs per country. The effect estimates of the SNPs from the discov-
ery stage (adjusted by PCAs) and the effect estimates from the replication were meta-analysed
using a inverse variance weighted meta-analysis(METAL version released 2011-03-25). [19].
We performed pathway analyses using ALIGATOR, a method for studying groups of genes by
testing for over-representation of members of those groups within lists of genes containing sig-
nificantly associated SNPs from GWA studies [20]. This analysis used 410 SNPs with a p-value
for significance of<0.001 out of 115,565 within-gene SNPs from a total of 279,389 available.
We found these SNPs were associated with 94 genes from a total of 13,092 genes with GO an-
notation covered in this study. Additionally we used Ingenuity Pathway Analysis (IPA) www.
ingenuity.com) to determine the functional pathways in the genes tagged by our top ranked
SNPs. We again selected those genes tagged by SNPs with p-value<0.001 and selected the ca-
nonical pathway analysis implemented in IPA software.
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Sequencing
We sequenced the 11 exons and intronic flanking areas of the GRM8 gene in 96 sCJD patients
using specific primers (S5 Table). The amplification reactions were carried out with 25 ng of
genomic DNA and 0.5 units of Taq DNA Polymerase in a volume of 25 μl. The final concentra-
tions of other reactants were: 1x Taq DNA Polymerase Buffer, 0.1 mM dNTPs and 0.1 μM of
each primer. The final concentration of MgCl2 was 2 mM for the amplification of exons 1–7
and 10; 4 mM for exons 8 and 9a; 1.5 mM for exon 9b and 1 mM for exon 11. Additionally, the
amplification reactions of exons 1 and 8 were supplied with DMSO 10% and 5%, respectively.
The PCR cycling conditions were as follows: initial denaturation at 96°C for 3 min followed by
30 cycles of 96°C for 30 s, annealing temperature (see S5 Table) for 30 s and extension tempera-
ture of 72°C for 1 min with a final extension at 72°C for 10 min. A 2 μl aliquot of the amplifica-
tion reaction was sequenced using 0.1μM of the above primers.
Functional prediction analysis
Functional prediction analysis of genetic variants was performed by the use of FuncPred online
software (http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm) [21]. Exonic splicing enhancers
were analyzed by RESCUE-ESE Web Server (http://genes.mit.edu/burgelab/rescue-ese/) [22]
and PITA online software (http://genie.weizmann.ac.il/pubs/mir07/index.html) [23] was used
to assess potential micro-RNA target sites. We searched for correlations between our genetic
variants and eQTL in GTEX [24] and Genenetwork (http://genenetwork.nl:8080/
GeneNetwork/) [25].
Phenotypic correlations
We performed an immunohistochemical study in brain samples from 48 sCJD patients. The
rs6951643 genotype distribution was as follows: 13 AA, 25 AG, and 9 GG. Sections from the
hippocampal region CA1 sub-region, temporal cortex and white matter were immunostained
for mGluR8. The intensity of mGluR8 (1:50; polyclonal rabbit antibody, Novus Biologicals,
Cambridge, UK) immunostaining was evaluated using a scale of 0–3 (0: no; 1: weak; 2: moder-
ate; 3: strong staining). The frequency of mGluR8 positive cells was scored semi-quantitatively
using three categories: 1,<10%; 2, 10–50%; 3,>50% and was evaluated to provide information
about the relative number of mGluR8 positive cells within the tissue. The product of these two
values (intensity and frequency scores) was used to give the overall scores (total scores). In ad-
jacent sections microglial activation using immunostaining for HLA-DP, DQ, DR (clone CR3/
43, 1:00, monoclonal mouse), and spongiosis were also estimated semi-quantitatively. The
analysis was performed (GGK) blinded to rs6951643 genotype. Ordinal regression was em-
ployed to test for association between rs6951643 genotypes and brain semi-quantitative expres-
sion of mGluR8. We adjusted by disease duration, PRNPM129V genotype, gliosis and
spongiosis. We correlated clinical variables (age at death and patient’s disease onset) with the
presence of 0, 1 or 2 sCJD risk alleles. In order to assess rs6951643 influence on age at onset
and disease duration we performed a time to event analysis using Cox regression adjusting by
PRNPM129V genotype and other relevant factors like sex and country of origin.
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S1 Fig. Q-Q plots for autosomal and X chromosome SNPs.
(TIF)
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S2 Fig. Genotype clusters of the five SNPs studied in stage three with Sequenom iPLEx
GOLD.
(TIF)
S3 Fig. Semi-quantitative assessments of mGluR8 expression in microglia (0 to 3) in the
temporal region across the three rs6951643 genotypes in 48 sCJD patients.
(TIF)
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